Cargando…

Cost drivers in the pharmacological treatment of interstitial lung disease

INTRODUCTION: Treatments of interstitial lung diseases (ILDs) mainly focus on disease stabilization and relief of symptoms by managing inflammation or suppressing fibrosis by (in part costly) drugs. To highlight economic burden of drug treatment in different ILD-subtypes we assessed cost trends and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maqhuzu, Phillen Nozibuyiso, Kreuter, Michael, Bahmer, Thomas, Kahn, Nicolas, Claussen, Martin, Holle, Rolf, Schwarzkopf, Larissa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335870/ https://www.ncbi.nlm.nih.gov/pubmed/34344376 http://dx.doi.org/10.1186/s12931-021-01807-8

Ejemplares similares

Determinants of health-related quality of life decline in interstitial lung disease
por: Maqhuzu, Phillen Nozibuyiso, et al.
Publicado: (2020)

Quality of life assessment in interstitial lung diseases:a comparison of the disease-specific K-BILD with the generic EQ-5D-5L
por: Szentes, Boglárka Lilla, et al.
Publicado: (2018)

Hospitalisation patterns of patients with interstitial lung disease in the light of comorbidities and medical treatment – a German claims data analysis
por: Wälscher, Julia, et al.
Publicado: (2020)

Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases – a claims data analysis
por: Schwarzkopf, Larissa, et al.
Publicado: (2018)

Effects of Influenza Vaccination in Patients with Interstitial Lung Diseases: An Epidemiological Claims Data Analysis
por: Marijic, Pavo, et al.
Publicado: (2022)

“Age matters”—German claims data indicate disparities in lung cancer care between elderly and young patients
por: Walter, Julia, et al.
Publicado: (2019)

Are community-living and institutionalized dementia patients cared for differently? Evidence on service utilization and costs of care from German insurance claims data
por: Schwarzkopf, Larissa, et al.
Publicado: (2013)

Effects of Nursing Home Residency on Diabetes Care in Individuals with Dementia: An Explorative Analysis Based on German Claims Data
por: Schwarzkopf, Larissa, et al.
Publicado: (2017)

Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases
por: Holtze, Colin, et al.
Publicado: (2018)

Health Care Service Utilization of Dementia Patients before and after Institutionalization: A Claims Data Analysis
por: Schwarzkopf, Larissa, et al.
Publicado: (2014)

A claims data-based comparison of comorbidity in individuals with and without dementia
por: Bauer, Kathrin, et al.
Publicado: (2014)

Excess costs of dementia disorders and the role of age and gender - an analysis of German health and long-term care insurance claims data
por: Schwarzkopf, Larissa, et al.
Publicado: (2012)

Interstitial lung diseases: course report
por: Kreuter, Michael, et al.
Publicado: (2018)

Interstitial lung disease:  course report
por: Kreuter, Michael, et al.
Publicado: (2020)

Official statistics and claims data records indicate non-response and recall bias within survey-based estimates of health care utilization in the older population
por: Hunger, Matthias, et al.
Publicado: (2013)

Interstitial lung diseases: course report
por: Kreuter, Michael, et al.
Publicado: (2016)

Interstitial lung diseases: course report
por: Kreuter, Michael, et al.
Publicado: (2019)

The world of rare interstitial lung diseases
por: Buschulte, Katharina, et al.
Publicado: (2023)

Predictors of Institutionalization of Dementia Patients in Mild and Moderate Stages: A 4-Year Prospective Analysis
por: Eska, Kathrin, et al.
Publicado: (2013)

Comorbidities in unclassifiable interstitial lung disease
por: Prior, Thomas Skovhus, et al.
Publicado: (2022)

Editorial: Interstitial Lung Disease Around the World
por: Wijsenbeek, Marlies, et al.
Publicado: (2022)

Fatum Inexorabile: Do Monocytes Predict the Fate of Interstitial Lung Abnormalities?
por: Kreuter, Michael, et al.
Publicado: (2022)

Diagnosis and Pharmacologic Management of Fibrotic Interstitial Lung Disease
por: Berger, Kristin, et al.
Publicado: (2023)

Cost-effectiveness of a non-pharmacological treatment vs. “care as usual” in day care centers for community-dwelling older people with cognitive impairment: results from the German randomized controlled DeTaMAKS-trial
por: Steinbeisser, Kathrin, et al.
Publicado: (2020)

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases
por: Torrisi, Sebastiano Emanuele, et al.
Publicado: (2019)

Pharmacologic Treatment of Anti-MDA5 Rapidly Progressive Interstitial Lung Disease
por: Selva-O’Callaghan, A., et al.
Publicado: (2021)

A New Tool to Assess Quality of Life in Patients with Idiopathic Pulmonary Fibrosis or Non-specific Interstitial Pneumonia
por: Kirsten, Detlef, et al.
Publicado: (2021)

Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study
por: Marijic, Pavo, et al.
Publicado: (2021)

Epidemiology, healthcare utilization, and related costs among patients with IPF: results from a German claims database analysis
por: Kreuter, Michael, et al.
Publicado: (2022)

Treatment choice, duration, and cost in patients with interstitial cystitis and painful bladder syndrome
por: Anger, Jennifer T., et al.
Publicado: (2010)

Comparing outcomes of ILD patients managed in specialised versus non-specialised centres
por: Marijic, Pavo, et al.
Publicado: (2022)

Updates in using a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples
por: Crespo, Andrea, et al.
Publicado: (2020)

Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence
por: Richeldi, Luca, et al.
Publicado: (2018)

Health-related quality of life associates with change in FEV(1) in COPD: results from the COSYCONET cohort
por: Lutter, Johanna I., et al.
Publicado: (2020)

Drug Induced Interstitial Lung Disease
por: Schwaiblmair, Martin, et al.
Publicado: (2012)

BreathEase: rationale, design and recruitment of a randomised trial and embedded mixed-methods study of a multiprofessional breathlessness service in early palliative care
por: Schunk, Michaela, et al.
Publicado: (2021)

Effects of nintedanib by inclusion criteria for progression of interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

The Non-Linear Relationship between BMI and Health Care Costs and the Resulting Cost Fraction Attributable to Obesity
por: Laxy, Michael, et al.
Publicado: (2017)

Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era
por: Nakshbandi, Gizal, et al.
Publicado: (2021)

Empirical analysis shows reduced cost data collection may be an efficient method in economic clinical trials
por: Seidl, Hildegard, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7cvddqj42kap8s8e9mhlcbgbou